Quick Facts
| Property | Value |
|---|---|
| Category | Long-Acting IGF-1 Analog |
| Risk Level | High |
| Administration | Subcutaneous Injection |
| Typical Frequency | Daily |
| Estimated Half-Life | Approximately 20–30 Hours |
| Primary Research Interest | Muscle Growth / Recovery / Nutrient Partitioning |
This material is provided strictly for educational and informational purposes related to peptide research and performance-enhancing compounds. IGF-1 LR3 is a potent biologically active growth factor analog that may significantly alter glucose metabolism, cellular growth signaling, and endocrine function. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
1. Reconstitution Guide
- Vial Size: 1 mg
- Dilutant Type: Dilute Acetic Acid Solution
- Amount of Dilutant Added: 2 mL
- Final Concentration: 0.50 mg/mL (500 mcg/mL)
At this concentration:
• 20 mcg = 0.040 mL (4.0 units)
• 60 mcg = 0.120 mL (12.0 units)
• 100 mcg = 0.200 mL (20.0 units)
2. Route of Administration
IGF-1 LR3 is most commonly administered as a subcutaneous injectable growth factor analog.
- Primary Route: SubQ Injection
- Preferred Timing: Pre-workout or post-workout depending on intended effect
- Administration Notes: Workout timing strategies are heavily emphasized within performance-enhancement discussions
3. Typical Research Protocols
- Product Strength: 0.50 mg/mL (500 mcg/mL)
- Typical Delivered Amount: 20–60 mcg daily, not to exceed 100 mcg per day
- Frequency: Daily, before or after a workout depending on the desired effect
- Cycle Length: 12 weeks on / 12 weeks off
- Special Notes: Some users strongly prefer pre-workout administration because they believe it enhances muscle pump, vascularity, and training synergy. Others prefer post-workout administration, believing it may improve nutrient uptake, satellite cell activation, and recovery signaling.
4. Summary
IGF-1 LR3 is a modified long-acting analog of insulin-like growth factor 1 (IGF-1) designed to extend circulating activity compared to native IGF-1.
Research and performance-enhancement interest in IGF-1 LR3 primarily centers around muscle growth, recovery support, nutrient partitioning, and anabolic signaling.
5. Mechanism of Action
IGF-1 LR3 functions by activating IGF-1 receptors involved in anabolic signaling, cellular growth pathways, nutrient uptake, and tissue recovery.
- Enhanced nutrient partitioning
- Satellite cell activation
- Increased protein synthesis signaling
- Improved muscle recovery signaling
- Enhanced glucose uptake
- Cellular growth pathway activation
6. Potential Benefits
- Potential lean muscle mass enhancement
- Improved workout recovery
- Enhanced nutrient partitioning
- Increased muscle fullness or “pump” effects
- Potential improvements in training performance
- Recovery signaling support
7. Potential Risks / Side Effects
High
- Hypoglycemia
- Water retention
- Headaches
- Dizziness
- Fatigue
- Abnormal tissue growth concerns
- Potential organ growth signaling concerns
- Insulin sensitivity alterations
- Potential cancer signaling concerns
8. Half-Life
IGF-1 LR3 is commonly discussed as having an estimated half-life of approximately 20–30 hours.
This extended duration is substantially longer than native IGF-1 and contributes to its popularity in performance-enhancement discussions.
9. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
- Avoid prolonged room temperature exposure
10. Contraindications / Warnings
- Active cancer or cancer history
- Diabetes or hypoglycemia disorders
- Pregnancy or breastfeeding
- Use alongside other potent anabolic growth factors
- Known hypersensitivity to peptide compounds
11. Research References
- PubMed
- NIH Publications
- IGF signaling and endocrinology literature
- Peer-reviewed anabolic signaling journals
CKF Tide Tables 